With this aim, we prospectively evaluated myeloidderived suppressor cell frequency and functional activity during immunotherapy for lung cancer. In this patient with stage III nonesmall-cell lung cancer, durvalumab in maintenance promoted a strong reduction in both myeloid-derived suppressor cell1 frequency and activity, as well as in the expression of immunosuppression-associated genes.

Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report

BERTELLI, GIACOMO;Trovato, Rosalinda;Ugel, Stefano;Bria, Emilio;Milella, Michele;Bronte, Vincenzo;Pilotto, Sara
2019

Abstract

With this aim, we prospectively evaluated myeloidderived suppressor cell frequency and functional activity during immunotherapy for lung cancer. In this patient with stage III nonesmall-cell lung cancer, durvalumab in maintenance promoted a strong reduction in both myeloid-derived suppressor cell1 frequency and activity, as well as in the expression of immunosuppression-associated genes.
Immunotherapy; MDSC; NSCLC; Predictive biomarkers; Tumor-induced immunosuppression
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/997929
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact